NHLBI

The funding will support research projects using data from the Trans Omics for Precision Medicine program to uncover disease pathology.

Eleven new studies from the NHLBI NextGen Consortium show different uses for iPSCs to study polygenetic diseases across various systems in the human body.

The partners are developing an assay to detect minimal residual disease in leukemia patients, for use with Sellas' investigational AML drug.

Funded projects will support the agency's Trans Omics for Precision Medicine program, which is focused on heart, lung, blood, and sleep disorders.

The CCHMC will act as the coordinating center for members of the NHLBI's Cardiovascular Development Consortium and Pediatric Cardiac Genomics Consortium.

The center has already sequenced and analyzed 1,500 human genomes for the TOPMed program and will expand this effort with the new funding.

The funding will support the Broad's sequencing of 20,000 individuals as part of the NHLBI's Trans-Omic for Precision Medicine program. 

WiCell will distribute human pluripotent stem cell lines created as part of NHLBI's Next Generation Genetic Association Studies. 

By combining genome-wide association and mRNA expression data, a National Heart, Lung, and Blood Institute-led team uncovered gene networks involved in blood pressure regulation.